KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.
1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2016, last updated on 1/8/2019, retrieved on 3/31/2019
2.) International Trade Association, "2016 Top Markets Report Pharmaceuticals, 2016". Retrieved 3/31/2019.
3.) World Health Organization, 2016. Data as of 1/8/2019, retrieved on 3/31/2019.
NAV | |
Net Asset Value | $38.26 |
Daily Change | 1.07% |
Price | |
Market Price | $38.32 |
Daily Change | 0.97% |
30 Day Median Bid/Ask Spread | |
Value | 0.4% |
The ETF’s 30 Day Median Bid-Ask Spread is calculated by identifying the ETF’s national best bid and national best offer ("NBBO") as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage rounded to the nearest hundredth.
Cumulative %Data as of: 03/31/2021 | Fund NAV | Closing Price | Index |
1 Month | -4.35% | -3.04% | -4.56% |
3 Month | -1.72% | -0.31% | -1.09% |
6 Month | 14.33% | 16.07% | 15.28% |
Since Inception | 54.22% | 56.80% | 57.76% |
Avg Annualized % Data as of quarter end: 03/31/2021 | Fund NAV | Closing Price | Index |
1 Year | 61.02% | 63.78% | 63.50% |
3 Year | 13.10% | 13.04% | 13.65% |
Since Inception | 14.66% | 15.26% | 15.50% |
*Fee waivers are contractual and in effect until August 2021
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.
The Growth of $10,000 chart reflects an initial investment of $10,000 on the day prior to the selected time period and assumes reinvestment of dividends and capital gains. For the growth of $10,000 chart since inception, the initial investment of $10,000 is instead made on the inception date of the Fund. Fund expenses, including management fees and other expenses were deducted. The growth of a $10,000 investment in the fund is hypothetical and for illustration purposes only.
Rank | Company Name | % of Net Assets | Ticker | Identifier | Shares Held | Market Value($) |
1 | WUXI BIOLOGICS CAYMAN INC | 8.93% | 2269 | KYG970081173 | 1,457,135 | 19,137,438 |
2 | JIANGSU HENGRU-A | 5.85% | 600276 | CNE0000014W7 | 922,074 | 12,535,031 |
3 | SHENZHEN MINDR-A | 5.16% | 300760 | CNE100003G67 | 182,899 | 11,045,726 |
4 | BEIGENE LTD-ADR | 3.90% | BGNE | US07725L1026 | 27,847 | 8,362,733 |
5 | WUXI APPTEC CO LTD-A | 3.73% | 603259 | CNE1000031K4 | 388,984 | 7,993,209 |
6 | CHONGQING ZHIF-A | 3.56% | 300122 | CNE100000V20 | 276,049 | 7,616,774 |
7 | ZAI LAB LTD-ADR | 3.31% | ZLAB | US98887Q1040 | 43,970 | 7,091,921 |
8 | ALIBABA HEALTH | 3.11% | 241 | BMG0171K1018 | 2,362,000 | 6,669,184 |
9 | AIER EYE HSPTL-A | 3.07% | 300015 | CNE100000GR6 | 722,648 | 6,585,737 |
10 | CSPC PHARMACEUTI | 3.02% | 1093 | HK1093012172 | 5,440,889 | 6,459,960 |
Holdings are subject to change.
Hyperlinks on this website are provided as a convenience and we disclaim any responsibility for information, services or products found on the websites linked hereto.
Click here to continue